<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37026057</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and clinical characteristics of Epstein-Barr virus infection among children in Shanghai, China, 2017-2022.</ArticleTitle><Pagination><StartPage>1139068</StartPage><MedlinePgn>1139068</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1139068</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2023.1139068</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate the epidemiology and infectious characteristics of Epstein-Barr virus (EBV) infection among children in Shanghai, China from 2017 to 2022.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective analysis of 10,260 inpatient patients who were subjected EBV nucleic acid testing from July 2017 to December 2022. Demographic information, clinical diagnosis, laboratory findings, etc. were collected and analyzed. EBV nucleic acid testing were performed by real-time PCR.</AbstractText><AbstractText Label="RESULTS">A total of 2192 (21.4%) inpatient children were EBV-positive, with the average age of 7.3 &#xb1; 0.1 y. EBV detection was stable from 2017 to 2020 (26.9~30.1%), but showed essential decreases in 2021 (16.0%) and 2022 (9.0%). EBV was highest (&gt;30%) detected from three quarters (Q) including 2018-Q4, 2019-Q4 and 2020-Q3. There were 24.5% of EBV coinfection with other pathogens, including bacteria (16.8%), other viruses (7.1%) and fungi (0.7%). EBV viral loads increased when coinfecting with bacteria ((142.2 &#xb1; 40.1) &#xd7;10<sup>4</sup>/mL) or other viruses ((165.7 &#xb1; 37.4) &#xd7;10<sup>4</sup>/mL). CRP significantly increased in EBV/fungi coinfection, while procalcitonin (PCT) and IL-6 showed remarkable increases in EBV/bacteria coinfection. Most (58.9%) of EBV-associated diseases belonged to immune disorders. The primary EBV-related diseases were systemic lupus erythematosus (SLE, 16.1%), immunodeficiency (12.4%), infectious mononucleosis (IM, 10.7%), pneumonia (10.4%) and Henoch-schonlein purpura (HSP, 10.2%). EBV viral loads were highest ((233.7 &#xb1; 27.4) &#xd7; 10<sup>4</sup>/mL) in patients with IM.</AbstractText><AbstractText Label="CONCLUSION">EBV was prevalent among children in China, the viral loads increased when coinfecting with bacteria or other viruses. SLE, immunodeficiency and IM were the primary EBV-related diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Ye, Chen, Zhong, Cao, Fu and Xu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhicheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Luxi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Huaqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lingfeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein-Barr virus</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">coinfection</Keyword><Keyword MajorTopicYN="N">immunodeficiency</Keyword><Keyword MajorTopicYN="N">infectious mononucleosis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>2</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37026057</ArticleId><ArticleId IdType="pmc">PMC10072160</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2023.1139068</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balfour H. J., Holman C. J., Hokanson K. M., Lelonek M. M., Giesbrecht J. E., White D. R., et al. . (2005). A prospective clinical study of epstein-barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis. 192 (9), 1505&#x2013;1512. doi:&#xa0;10.1086/491740</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/491740</ArticleId><ArticleId IdType="pubmed">16206064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. I. (2015). Primary immunodeficiencies associated with ebv disease. Curr. Top. Microbiol. Immunol. 390 (Pt 1), 241&#x2013;265. doi:&#xa0;10.1007/978-3-319-22822-8_10</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-22822-8_10</ArticleId><ArticleId IdType="pmc">PMC6349415</ArticleId><ArticleId IdType="pubmed">26424649</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Mattia G., Nenna R., Mancino E., Rizzo V., Pierangeli A., Villani A., et al. . (2021). During the covid-19 pandemic where has respiratory syncytial virus gone? Pediatr. Pulmonol. 56 (10), 3106&#x2013;3109. doi:&#xa0;10.1002/ppul.25582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.25582</ArticleId><ArticleId IdType="pmc">PMC8441855</ArticleId><ArticleId IdType="pubmed">34273135</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A. H., Sandhu N., Larsen N., Lisander L. J., Jacobsen S., Houen G. (2016). Impaired cytokine responses to epstein-barr virus antigens in systemic lupus erythematosus patients. J. Immunol. Res. 2016, 6473204. doi:&#xa0;10.1155/2016/6473204</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6473204</ArticleId><ArticleId IdType="pmc">PMC4826706</ArticleId><ArticleId IdType="pubmed">27110576</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunmire S. K., Verghese P. S., Balfour H. J. (2018). Primary epstein-barr virus infection. J. Clin. Virol. 102, 84&#x2013;92. doi:&#xa0;10.1016/j.jcv.2018.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.03.001</ArticleId><ArticleId IdType="pubmed">29525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fafi-Kremer S., Brengel-Pesce K., Bargues G., Bourgeat M. J., Genoulaz O., Seigneurin J. M., et al. . (2004). Assessment of automated dna extraction coupled with real-time pcr for measuring epstein-barr virus load in whole blood, peripheral mononuclear cells and plasma. J. Clin. Virol. 30 (2), 157&#x2013;164. doi:&#xa0;10.1016/j.jcv.2003.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2003.10.002</ArticleId><ArticleId IdType="pubmed">15125872</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman C., Anderson R. (2021). The role of co-infections and secondary infections in patients with covid-19. Pneumonia (Nathan). 13 (1), 5. doi:&#xa0;10.1186/s41479-021-00083-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41479-021-00083-w</ArticleId><ArticleId IdType="pmc">PMC8068564</ArticleId><ArticleId IdType="pubmed">33894790</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu P., Xu H., Jing C., Deng J., Wang H., Hua C., et al. . (2021). Bacterial epidemiology and antimicrobial resistance profiles in children reported by the isped program in China 2016 to 2020. Microbiol. Spectr. 9 (3), e28321. doi:&#xa0;10.1128/Spectrum.00283-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00283-21</ArticleId><ArticleId IdType="pmc">PMC8567242</ArticleId><ArticleId IdType="pubmed">34730410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugl A., Andersen C. L. (2019). Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam. Pract. 20 (1), 62. doi:&#xa0;10.1186/s12875-019-0954-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-019-0954-3</ArticleId><ArticleId IdType="pmc">PMC6518816</ArticleId><ArticleId IdType="pubmed">31088382</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara S., Nakamura H. (2020). Chronic active epstein-barr virus infection: is it immunodeficiency, malignancy, or both? Cancers (Basel). 12 (11), 3202. doi:&#xa0;10.3390/cancers12113202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12113202</ArticleId><ArticleId IdType="pmc">PMC7692233</ArticleId><ArticleId IdType="pubmed">33143184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L. W., Xie Z. D., Liu Y. Y., Wang Y., Shen K. L. (2011). Epidemiologic and clinical characteristics of infectious mononucleosis associated with epstein-barr virus infection in children in beijing, china. World J. Pediatr. 7 (1), 45&#x2013;49. doi:&#xa0;10.1007/s12519-011-0244-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-011-0244-1</ArticleId><ArticleId IdType="pubmed">21191775</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Peris M., Jimenez C. M., Manes J. Y., Pariente M. M., Gonzalez G. D., Calvo R. F. (2019). [epstein-barr virus primary infection in healthy children]. Pediatr. (Engl. Ed). 90 (6), 376&#x2013;385. doi:&#xa0;10.1016/j.anpedi.2018.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anpedi.2018.09.003</ArticleId><ArticleId IdType="pubmed">30529045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gequelin L. C., Riediger I. N., Nakatani S. M., Biondo A. W., Bonfim C. M. (2011). Epstein-Barr virus: General factors, virus-related diseases and measurement of viral load after transplant. Rev. Bras. Hematol. Hemoter. 33 (5), 383&#x2013;388. doi:&#xa0;10.5581/1516-8484.20110103</Citation><ArticleIdList><ArticleId IdType="doi">10.5581/1516-8484.20110103</ArticleId><ArticleId IdType="pmc">PMC3415781</ArticleId><ArticleId IdType="pubmed">23049344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulley M. L. (2001). Molecular diagnosis of epstein-barr virus-related diseases. J. Mol. Diagn. 3 (1), 1&#x2013;10. doi:&#xa0;10.1016/S1525-1578(10)60642-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1525-1578(10)60642-3</ArticleId><ArticleId IdType="pmc">PMC1907346</ArticleId><ArticleId IdType="pubmed">11227065</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J. B., Chen X., , Pujato M., Miller D., Maddox A., Forney C., et al. . (2018). Transcription factors operate across disease loci, with ebna2 implicated in autoimmunity. Nat. Genet. 50 (5), 699&#x2013;707. doi:&#xa0;10.1038/s41588-018-0102-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0102-3</ArticleId><ArticleId IdType="pmc">PMC6022759</ArticleId><ArticleId IdType="pubmed">29662164</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G., Trier N. H. (2020). Epstein-Barr virus and systemic autoimmune diseases. Front. Immunol. 11. doi:&#xa0;10.3389/fimmu.2020.587380</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayasooriya S., de Silva T. I., Njie-jobe J., Sanyang C., Leese A. M., Bell A. I., et al. . (2015). Early virological and immunological events in asymptomatic epstein-barr virus infection in african children. PloS Pathog. 11 (3), e1004746. doi:&#xa0;10.1371/journal.ppat.1004746</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004746</ArticleId><ArticleId IdType="pmc">PMC4376400</ArticleId><ArticleId IdType="pubmed">25816224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jog N. R., James J. A. (2020). Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front. Immunol. 11. doi:&#xa0;10.3389/fimmu.2020.623944</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.623944</ArticleId><ArticleId IdType="pmc">PMC7886683</ArticleId><ArticleId IdType="pubmed">33613559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M. S., Kieff E. (2015). Epstein-Barr virus latent genes. Exp. Mol. Med. 47 (1), e131. doi:&#xa0;10.1038/emm.2014.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.84</ArticleId><ArticleId IdType="pmc">PMC4314583</ArticleId><ArticleId IdType="pubmed">25613728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasifoglu N., Oz S., Dinleyici E. C., Us T., Bor O., Durmaz G., et al. . (2018). Comparison of methods used for the diagnosis of epstein-barr virus infections in children. Pol. J. Microbiol. 67 (1), 81&#x2013;88. doi:&#xa0;10.5604/01.3001.0010.6287</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/01.3001.0010.6287</ArticleId><ArticleId IdType="pubmed">30015428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino C., Ghosh S. (2021). Epstein-Barr virus in inborn immunodeficiency-more than infection. Cancers (Basel). 13 (19), 4752. doi:&#xa0;10.3390/cancers13194752</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13194752</ArticleId><ArticleId IdType="pmc">PMC8507541</ArticleId><ArticleId IdType="pubmed">34638238</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T., Tsurumi T. (2014). Switching of ebv cycles between latent and lytic states. Rev. Med. Virol. 24 (3), 142&#x2013;153. doi:&#xa0;10.1002/rmv.1780</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1780</ArticleId><ArticleId IdType="pubmed">24339346</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem A., Suresh K., Awais H., Waseem S. (2021). Epstein-Barr virus coinfection in covid-19. J. Investig. Med. High Impact Case Rep. 9, 1605888370. doi:&#xa0;10.1177/23247096211040626</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23247096211040626</ArticleId><ArticleId IdType="pmc">PMC8392798</ArticleId><ArticleId IdType="pubmed">34428954</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P. D., Alghareeb R., Hussain A., Maheshwari M. V., Khalid N. (2022). The association of epstein-barr virus with cancer. Cureus 14 (6), e26314. doi:&#xa0;10.7759/cureus.26314</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.26314</ArticleId><ArticleId IdType="pmc">PMC9314235</ArticleId><ArticleId IdType="pubmed">35911302</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T., Huang L., Tian J. (2022). Prevalence of epstein-barr viral dna among children at a single hospital in suzhou, china. J. Pediatr. (Rio J). 98 (2), 142&#x2013;146. doi:&#xa0;10.1016/j.jped.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jped.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC9432126</ArticleId><ArticleId IdType="pubmed">34174213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollid L. M. (2022). Epstein-Barr virus as a driver of multiple sclerosis. Sci. Immunol. 7 (70), 7799. doi:&#xa0;10.1126/sciimmunol.abo7799</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abo7799</ArticleId><ArticleId IdType="pubmed">35363541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J. W., Bialasiewicz S., Dwyer D. E., Dilcher M., Tellier R., Taylor J., et al. . (2021). Where have all the viruses gone? disappearance of seasonal respiratory viruses during the covid-19 pandemic. J. Med. Virol. 93 (7), 4099&#x2013;4101. doi:&#xa0;10.1002/jmv.26964</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26964</ArticleId><ArticleId IdType="pmc">PMC8250511</ArticleId><ArticleId IdType="pubmed">33760278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye S. G., Latour S. (2020). Primary immunodeficiencies reveal the molecular requirements for effective host defense against ebv infection. Blood 135 (9), 644&#x2013;655. doi:&#xa0;10.1182/blood.2019000928</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019000928</ArticleId><ArticleId IdType="pubmed">31942615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Xu H., Han J., Jin R., Chen H. (2022). How does epstein-barr virus interact with other microbiomes in ebv-driven cancers? Front. Cell Infect. Microbiol. 12. doi:&#xa0;10.3389/fcimb.2022.852066</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.852066</ArticleId><ArticleId IdType="pmc">PMC8904896</ArticleId><ArticleId IdType="pubmed">35281433</ArticleId></ArticleIdList></Reference><Reference><Citation>Worth A. J., Houldcroft C. J., Booth C. (2016). Severe epstein-barr virus infection in primary immunodeficiency and the normal host. Br. J. Haematol. 175 (4), 559&#x2013;576. doi:&#xa0;10.1111/bjh.14339</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14339</ArticleId><ArticleId IdType="pubmed">27748521</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong G., Zhang B., Huang M. Y., Zhou H., Chen L. Z., Feng Q. S., et al. . (2014). Epstein-Barr virus (ebv) infection in chinese children: A retrospective study of age-specific prevalence. PloS One 9 (6), e99857. doi:&#xa0;10.1371/journal.pone.0099857</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099857</ArticleId><ArticleId IdType="pmc">PMC4051769</ArticleId><ArticleId IdType="pubmed">24914816</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>